Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 1.00 |
| ▸ | S1PR3 | Q99500 | 20/20 | 1.00 |
| ▸ | S1PR2 | O95136 | 18/20 | 1.00 |
| ▸ | LPAR2 | Q9HBW0 | 11/20 | 1.00 |
| ▸ | S1PR4 | O95977 | 6/20 | 1.00 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14195630 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL14195631 | 1.00 | S1PR1 (1.00) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL14195743 | 0.96 | S1PR1 (1.00) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL14195749 | 0.96 | S1PR1 (1.00) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL14195746 | 0.94 | S1PR1 (0.97) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL5214558 | 0.94 | S1PR1 (0.88) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL14195646 | 0.90 | S1PR1 (1.00) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL14195652 | 0.90 | S1PR1 (1.00) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL14195767 | 0.89 | S1PR1 (0.80) | S1PR1S1PR3S1PR2LPAR2S1PR4 | |
| SCHEMBL4875751 | 0.89 | S1PR1 (0.80) | S1PR1S1PR3S1PR2LPAR2S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575964-B1 | N-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATES, PHOSPHONATES AND TETRAZOLES AS EDG RECEPTOR AGONISTS | MERCK & CO INC (US) | 2009-11-11 | — | — | EP | disclosed |
| US-7351725-B2 | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351725-B2 | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351725-B2 | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists | MERCK & CO., INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20050070506-A1 | Selective s1p1/edg1 receptor agonists | DOHERTY GEORGE A (US) | 2005-03-31 | — | — | US | disclosed |
| US-20050020837-A1 | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists | MERCK SHARP & DOHME CORP. | 2005-01-27 | — | — | US | disclosed |
| US-20040058894-A1 | Selective S1P1/Edg1 receptor agonists | DOHERTY GEORGE A (US) | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070506-A1 | Selective s1p1/edg1 receptor agonists | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR3 2/4885S1PR2 4/4885 |
| US-20040058894-A1 | Selective S1P1/Edg1 receptor agonists | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885S1PR2 3/4885 |
| US-20050020837-A1 | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists | EDNRA, ADGRE5, GPR65 | S1PR1 286/4885S1PR3 254/4885S1PR2 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.